VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (4507)	4/1/1998 4:13:00 PM
From: biowa	Read Replies (1) of 9719

Peter, >>I can see this as reducing the risks of biotech, but also maybe reducing the rewards<< Actually, IMO it might increase the opportunities by making less sizable and more complex indications more economically attractive. In other words, if the economic incentive is there now to attack problems of a given riskiness, then as risk is reduced biotech will expand into indications that are currently too risky (but are subsequently lowered below the risk cut-off level). As for absolute cost, I think that you'll always have to pay more for better CUTTING-EDGE performance. Looking at a given technology, however, the price should decrease. biowa

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next